Logo Logo
Hilfe
Hilfe
Switch Language to English

Hasseli, R.; Pfeil, A.; Hoyer, B. F.; Krause, A.; Lorenz, H. -M.; Richter, J. G.; Schmeiser, T.; Voll, R. E.; Schulze-Koops, H.; Specker, C. und Mueller-Ladner, U. (2021): Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis? In: Clinical and Experimental Rheumatology, Bd. 39, Nr. 3: S. 639-647

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Objective Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are the most common inflammatory rheumatic diseases (IRD). The aim of this study was to elucidate differences in the outcome of SARS-CoV-2 infection in RA-and SpA-patients. Methods Data from the German COVID-19 registry for IRD patients from 30th March to 16th November 2020 were analysed. 208 RA and SpA patients were included in the study, matched for gender and age. Results 104 SpA patients (40% patients with ankylosing spondylitis, 54% with psoriatic arthritis and 6% with enteropathic arthritis) were compared to 104 RA patients. For both groups, median age was 56 years. TNF-i treatment was reported in 45% of the SpA and in 19% of RA patients (p=0.001). Glucocorticoids were used in 13% of the SpA and in 40% of the RA patients (p=0.001). In both groups, the majority of the patients (97% SpA, 95% RA) recovered from COVID-19. Hospitalisation was needed in 16% of the SpA and in 30% of the RA patients (p=0.05), and oxygen treatment in 10% and 18% respectively (p=ns). Three versus six (p=ns) fatal courses were reported in the SpA versus the RA group. Conclusion The study revealed that the hospitalisation rate during COVID-19 infection, but not the mortality, was significantly higher in RA as compared to SpA patients. This could be explained either by different treatment strategies or by different susceptibilities of the two diseases.

Dokument bearbeiten Dokument bearbeiten